Tuesday 12 February 2019

Reuters Health Report: Indivior loses U.S. district court battle, copycat launches imminent

Reuters.com Newsletter

Indivior loses U.S. district court battle, copycat launches imminent

Generic competitors to British drugmaker Indivior Plc's blockbuster opioid addiction treatment are on course to launch sales next week after the firm's attempt to stay a U.S. District court judgement was rejected.

Merck, Pfizer combo treatment boosts kidney cancer survival

Drugmaker Merck & Co Inc said on Monday that the combination of its cancer immunotherapy Keytruda with Pfizer Inc's Inlyta cut the risk of death nearly in half for patients with the most common form of kidney cancer when compared with treatment with chemotherapy drug Sutent.

One in six U.S. kids have mental health disorders

(Reuters Health) - Roughly in six U.S. kids have at least one mental health disorder, and only about half of them receive treatment from a mental health professional, a new study suggests.

Gilead misses key goal in NASH liver disease trial, shares sink

Gilead Sciences Inc said on Monday that a late-stage study of a key experimental drug aimed at treating NASH, a progressive fatty liver disease, failed to meet its main goal, sending the company's shares down 4.6 percent in after-hours trading.

Almost half of U.S. heart disease patients struggle with medical bills

(Reuters Health) - Roughly 45 percent of Americans under 65 who have cardiovascular disease experience financial hardships from medical bills, a U.S. study suggests.

Catalyst Pharma sees net price of drug, once free, topping $300,000

Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease, which had long been available to patients for free, will cost more than $300,000 per year including rebates to insurers and other discounts.

Kindergarten teachers' assessments may be linked with pupils' earnings as adults

(Reuters Health) - Boys whose teachers find them antisocial in kindergarten may have lower income as adults than their classmates who don't have behavior problems, a Canadian study suggests.

FDA rebukes 17 firms for selling fake Alzheimer's drugs

The U.S. Food and Drug Administration (FDA) has warned more than a dozen companies against selling unapproved products which claim to treat Alzheimer's disease and other serious ailments, the agency said on Monday.

Sanofi and Regeneron cut list price of cholesterol drug by 60 percent

Sanofi SA and Regeneron Pharmaceuticals Inc said on Monday that they will slash the U.S. list price of their potent but expensive cholesterol fighter Praluent by 60 percent, as the drugmakers follow a similar move by rival Amgen Inc in hopes of increasing use of the drug.

Dementia patient over-medicated and bruised when he died, widow tells Australian aged care inquiry

An elderly man suffering Parkinson's Disease and dementia was given 10 times his medication and had unexplained bruising when he died at an Australian aged care facility, his widow told an inquiry into the A$20 billion ($14 billion) aged care sector.

Seven mumps cases confirmed at Houston ICE detention facility

Seven adult detainees at a U.S. Immigration and Customs Enforcement detention facility in Houston have been diagnosed with mumps, but the contagious disease is contained, the city's health department said on Saturday.

Related Videos

Rap scores a breakthrough at the Grammy awards

INSIGHT: A look back at the Grammy Awards

Introducing the all-new
Reuters News app

The new Reuters News app is here, redesigned from the ground up to fit your busy life.

Get it now on iOS